KPTI Karyopharm Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KPTI

Price (delayed)

$1.75

Market cap

$39.69M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$14.16

Enterprise value

$240.59M

?
Relative Growth: Rel. Growth: 22
Relative Strength: Rel. Strength: 1
Relative Valuation: Rel. Valuation: 37
Relative Profitability: Rel. Profitability: 19

Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO ® (selinexor), is a ...

Highlights
The EPS has grown by 12% from the previous quarter and by 3.5% YoY
The revenue has grown by 7% YoY but it has contracted by 3% from the previous quarter
The company's gross profit rose by 6% YoY but it fell by 3.1% QoQ
The net income has plunged by 82% YoY and by 15% from the previous quarter
The equity has contracted by 38% YoY and by 24% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.karyopharm.com
Peers: MRK BMY ABT EXEL

Key stats

What are the main financial stats of KPTI

KPTI stock price

How has the Karyopharm Therapeutics stock price performed over time
Intraday
-3.85%
1 week
2.94%
1 month
-10.71%
1 year
-76.6%
YTD
-76.22%
QTD
-82.09%

Financial performance

How have Karyopharm Therapeutics's revenue and profit performed over time
Revenue
$146.62M
Gross profit
$140.59M
Operating income
-$82.35M
Net income
-$224.74M
Gross margin
95.9%
Net margin
-153.3%
The net income has plunged by 82% YoY and by 15% from the previous quarter
KPTI's net margin has plunged by 70% YoY and by 19% from the previous quarter
KPTI's operating margin is up by 33% YoY
KPTI's operating income is up by 29% YoY and by 2.2% QoQ

Price vs fundamentals

How does KPTI's price correlate with its fundamentals

Growth

What is Karyopharm Therapeutics's growth rate over time

Valuation

What is Karyopharm Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.64
The EPS has grown by 12% from the previous quarter and by 3.5% YoY
The equity has contracted by 38% YoY and by 24% from the previous quarter
The P/S is 72% lower than the 5-year quarterly average of 1.3 and 60% lower than the last 4 quarters average of 0.9
The revenue has grown by 7% YoY but it has contracted by 3% from the previous quarter

Efficiency

How efficient is Karyopharm Therapeutics business performance
Karyopharm Therapeutics's return on invested capital has shrunk by 158% YoY and by 15% QoQ
KPTI's ROA has shrunk by 138% YoY and by 14% QoQ
The ROS has plunged by 109% YoY and by 23% from the previous quarter

Dividends

What is KPTI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KPTI.

Financial health

How did Karyopharm Therapeutics financials performed over time
KPTI's total assets is 75% smaller than its total liabilities
KPTI's total liabilities is up by 28% YoY and by 11% QoQ
Karyopharm Therapeutics's quick ratio has decreased by 28% from the previous quarter and by 17% YoY
KPTI's debt is 178% more than its equity
The equity has contracted by 38% YoY and by 24% from the previous quarter
KPTI's debt is up by 34% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.